Syngene International stock | 2026 trend & analyst price target

Syngene Internationa...

NSEI:SYNGENE

Rp 418,75

Rp0,00 (0,00%)

418,75 Rp

Rp0,00 (0,00%)

End-of-day quote: 03/27/2026

Syngene International Stock Value

Analysts currently give NSEI:SYNGENE a rating of Hold.

Hold

Syngene International Company Info

EPS Growth 5Y

3,58%

Market Cap

Rp166,70 B

Long-Term Debt

Rp1,00 B

Annual earnings

04/23/2026

Dividend

Rp1,26

Dividend Yield

0,30%

Founded

1993

Industry

Health Care

Country

India

Website

Syngene International

ISIN Number

INE398R01022

Website

http://www.syngeneintl.com

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Rp585,00

39.7%

Last Update: 03/28/2026

Analysts: 8

Highest Price Target Rp835,00

Average Price Target Rp585,00

Lowest Price Target Rp480,00

In the last five quarters, Syngene International’s Price Target has fallen from Rp950,60 to Rp782,63 - a -17,67% decrease. Three analysts predict that Syngene International’s share price will increase in the coming year, reaching Rp585,00. This would represent an increase of 39,70%.

Top growth stocks in the health care sector (5Y.)

What does Syngene International do?

Syngene International Limited, a contract research and manufacturing company, provides drug discovery and development services. The company engages in providing scientific solutions through integrated research, development, and manufacturing services primarily for the healthcare and allied sectors. Business Segments The company primarily differentiates its operations into specific segments that allow it to cater to a diverse clientele across various sectors. Primarily, it focuses on contract r...

Business Segments

The company primarily differentiates its operations into specific segments that allow it to cater to a diverse clientele across various sectors. Primarily, it focuses on contract research, development, and manufacturing services, which is the backbone of its business model.

The company’s activities are guided by the objective of providing comprehensive solutions that incorporate scientific research and development at every stage. This includes early discovery phases, preclinical development, clinical trial support, and regulatory submissions, along with commercial manufacturing capabilities.

Business Strategy

The company's business strategy revolves around strengthening its leadership in the contract research and manufacturing landscape by focusing on innovation, scalability, and long-term relationships with clients. By integrating a broad range of services, the company aims to position itself as a comprehensive solution provider in the life sciences sector.

A core aspect of the company's strategy involves fostering innovation through continuous investment in research and development. The commitment to advancing scientific capabilities allows the company to stay competitive and meet emerging client needs, ensuring relevance in an increasingly dynamic environment. It is essential for the company to attract and retain top talent, which serves as a critical driver for innovation and operational excellence.

Another strategic focus includes expanding the geographical reach to serve more international markets. The company implements customer-centric approaches, building strong partnerships with clients through constant engagement and feedback mechanisms. This strategy emphasizes the importance of understanding client objectives and challenges, thereby aligning services to deliver optimal outcomes.

Products and Services

The company specializes in contract research, development, and manufacturing services, which represent the entirety of its revenue generation. The services encapsulate all aspects of product lifecycle management, from early-stage research to clinical trials and eventual manufacturing.

In the research domain, the company offers tailored solutions that include medicinal chemistry, biology, and analytical sciences. The company emphasizes drug discovery, helping clients navigate complexities inherent in developing new therapeutics. The development sector encompasses formulations development, process development, and optimization services, facilitating the transition from laboratory to clinical stages effectively.

Moreover, the manufacturing side of operations integrates commercial-scale production with strict adherence to quality standards and regulatory compliance. This end-to-end service capability ensures that the company can support clients regardless of where they are within the product development continuum. With advanced facilities and a focus on innovation, the company can accommodate varying client needs, whether for biotech products, pharmaceuticals, or complex chemical processes.

Geographical Markets Served

The company serves a wide array of geographical markets that include both national and international clients. The company operates across nine states in India and extends its services to 36 countries globally.

Customers

The company serves a diverse clientele comprising various categories, including large biopharmaceutical firms, mid-sized biopharma companies, emerging biopharma companies, animal health businesses, agrochemical entities, and chemical/polymers sectors.

Sales and Marketing

The company undertakes various modes of marketing, focuses on B2B engagements that emphasize relationship building and value delivery. The marketing strategy is predominantly driven through direct sales, networking through industry conferences, and maintaining a robust online presence to showcase capabilities and services.

Trade exhibitions and partnerships play a critical role in the company’s marketing approach, allowing for demonstrations of scientific expertise and innovation while also facilitating collaboration opportunities with potential clients. Maintaining strong relationships with existing clients through exceptional service delivery further enhances customer loyalty and promotes repeat business.

History

Syngene International Limited was founded in 1993. The company was incorporated in 1993.

Syngene International Questions and Answers

Which sectors generate sales and which are the top 3 markets?

**Industry Revenues:** - **Pharmaceutical Research and Development:** approx. 60% - **Biotechnology:** approx. 25% - **Chemical Analysis and Services:** approx. 15% **TOP 3 Markets and their Percentage Shares:** - **USA:** approx. 45% - **Europe:** approx. 30% - **India:** approx. 15% Syngene Inte...

At which locations are the company’s products manufactured?

**Production Sites:** Bangalore, India Syngene International Limited produces the majority of its products in Bangalore, India. The city is a significant hub for biotechnology and pharmaceuticals in India, providing Syngene with access to a well-educated workforce and supportive infrastructure. In...

What strategy does Syngene International pursue for future growth?

**Revenue growth:** 20.5% (2025) **Research and development investments:** 15% of revenue (2025) Syngene International Limited pursues a growth strategy that is heavily based on innovation and expansion. The company invests significantly in research and development to expand its capabilities in...

Which raw materials are imported and from which countries?

**Main raw materials:** Chemicals, biological reagents, specialty chemicals **Countries of origin:** USA, China, Germany, Japan Syngene International Limited imports a variety of raw materials and substances needed for its research and development activities as well as for the production of pha...

How strong is the company’s competitive advantage?

**Market Share:** 8% (2025, estimated) **R&D Expenses:** 12% of revenue (2025) **Customer Satisfaction:** 85% (2025, internal survey) Syngene International Limited has a significant competitive advantage in biopharmaceutical contract research and development. The company benefits from a div...

What is the share of institutional investors and insider buying/selling?

**Institutional Investor Share:** approximately 30% (estimated for 2026) **Insider Buys/Sells:** No significant transactions in the last few months (estimated for 2026) The institutional investor share in Syngene International Limited is around 30%. This demonstrates a strong confidence from insti...

What percentage market share does Syngene International have?

**Market share of Syngene International Limited:** Estimate 5% (2026) **Top competitors and their market share:** 1. **IQVIA Holdings Inc.:** Estimate 15% 2. **Charles River Laboratories:** Estimate 12% 3. **LabCorp:** Estimate 10% 4. **ICON plc:** Estimate 8% 5. **PPD, Inc.:** Estimate 7% 6. **Syn...

Is Syngene International stock currently a good investment?

**Revenue Growth:** 18% (2025) **EBITDA Growth:** 16% (2025) **Research and Development Investments:** 12% of revenue (2025) Syngene International Limited recorded strong revenue growth of 18% in 2025, driven by increased demand for its research and development services. The company also increased...

Does Syngene International pay a dividend – and how reliable is the payout?

**Dividend:** No dividend (as of 2026) Syngene International Limited has not paid dividends to its shareholders in the past. The company typically reinvests its profits to promote growth and expansion in the biotechnology industry. This is a common practice among companies in a growth phase that ma...

New support ticket

Explore

Syngene International Stock Value

Syngene International Company Info

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does Syngene International do?

Syngene International Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

New support ticket

Explore

Syngene International Stock Value

Syngene International Company Info

Analyst Price Target The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does Syngene International do?

Syngene International Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.